Achieve Life Sciences, Inc. (NASDAQ:ACHV – Get Rating) – Research analysts at Zacks Small Cap raised their FY2023 earnings per share (EPS) estimates for shares of Achieve Life Sciences in a note issued to investors on Monday, March 20th. Zacks Small Cap analyst J. Vandermosten now anticipates that the biopharmaceutical company will earn ($1.82) per share for the year, up from their previous forecast of ($1.99). The consensus estimate for Achieve Life Sciences’ current full-year earnings is ($2.00) per share. Zacks Small Cap also issued estimates for Achieve Life Sciences’ FY2024 earnings at ($2.02) EPS.
Several other equities analysts have also commented on ACHV. Oppenheimer reaffirmed an “outperform” rating and issued a $17.00 price target on shares of Achieve Life Sciences in a research note on Friday, March 17th. Maxim Group reaffirmed a “buy” rating and issued a $8.00 price target on shares of Achieve Life Sciences in a research note on Friday, March 17th.
Achieve Life Sciences Stock Performance
Shares of Achieve Life Sciences stock opened at $4.71 on Thursday. Achieve Life Sciences has a 52 week low of $2.00 and a 52 week high of $8.13. The business’s fifty day simple moving average is $4.90 and its 200-day simple moving average is $3.62. The firm has a market cap of $84.45 million, a PE ratio of -1.17 and a beta of 1.44. The company has a quick ratio of 1.27, a current ratio of 1.27 and a debt-to-equity ratio of 0.01.
Achieve Life Sciences (NASDAQ:ACHV – Get Rating) last announced its quarterly earnings results on Thursday, March 16th. The biopharmaceutical company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.07. During the same period last year, the business posted ($0.76) earnings per share.
Hedge Funds Weigh In On Achieve Life Sciences
Several hedge funds have recently bought and sold shares of the company. Millennium Management LLC acquired a new position in Achieve Life Sciences during the 4th quarter worth about $75,000. Morgan Stanley lifted its stake in Achieve Life Sciences by 437.4% during the 4th quarter. Morgan Stanley now owns 13,547 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 11,026 shares in the last quarter. HRT Financial LP acquired a new position in Achieve Life Sciences during the 4th quarter worth about $32,000. Raymond James & Associates lifted its stake in Achieve Life Sciences by 412.0% during the 4th quarter. Raymond James & Associates now owns 89,249 shares of the biopharmaceutical company’s stock worth $219,000 after acquiring an additional 71,818 shares in the last quarter. Finally, LPL Financial LLC raised its position in Achieve Life Sciences by 48.4% in the 4th quarter. LPL Financial LLC now owns 148,300 shares of the biopharmaceutical company’s stock valued at $363,000 after purchasing an additional 48,400 shares in the last quarter. Institutional investors and hedge funds own 21.11% of the company’s stock.
About Achieve Life Sciences
Achieve Life Sciences, Inc is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
Receive News & Ratings for Achieve Life Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Achieve Life Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.